Timothy Cloughesy
Timothy Cloughesy
Подтвержден адрес электронной почты в домене mednet.ucla.edu
Название
Процитировано
Процитировано
Год
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
PY Wen, DR Macdonald, DA Reardon, TF Cloughesy, AG Sorensen, ...
Journal of clinical oncology 28 (11), 1963-1972, 2010
30282010
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
HS Friedman, MD Prados, PY Wen, T Mikkelsen, D Schiff, LE Abrey, ...
Journal of clinical oncology 27 (28), 4733-4740, 2009
24532009
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma
OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ...
New England Journal of Medicine 370 (8), 709-722, 2014
19672014
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff, MY Wang, I Vivanco, DA Haas-Kogan, S Zhu, EQ Dia, ...
New England Journal of Medicine 353 (19), 2012-2024, 2005
16172005
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma
R Beroukhim, G Getz, L Nghiemphu, J Barretina, T Hsueh, D Linhart, ...
Proceedings of the National Academy of Sciences 104 (50), 20007-20012, 2007
11262007
High-throughput oncogene mutation profiling in human cancer
RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ...
Nature genetics 39 (3), 347-351, 2007
10892007
Gene expression profiling of gliomas strongly predicts survival
WA Freije, FE Castro-Vargas, Z Fang, S Horvath, T Cloughesy, LM Liau, ...
Cancer research 64 (18), 6503-6510, 2004
7912004
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target
S Horvath, B Zhang, M Carlson, KV Lu, S Zhu, RM Felciano, MF Laurance, ...
Proceedings of the National Academy of Sciences 103 (46), 17402-17407, 2006
6512006
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma
TF Cloughesy, K Yoshimoto, P Nghiemphu, K Brown, J Dang, S Zhu, ...
PLoS medicine 5 (1), e8, 2008
6102008
Standards of care for treatment of recurrent glioblastoma—are we there yet?
M Weller, T Cloughesy, JR Perry, W Wick
Neuro-oncology 15 (1), 4-27, 2013
5712013
Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo
G Choe, S Horvath, TF Cloughesy, K Crosby, D Seligson, A Palotie, ...
Cancer research 63 (11), 2742-2746, 2003
5412003
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
DA Reardon, KL Fink, T Mikkelsen, TF Cloughesy, A O'Neill, S Plotkin, ...
Clinical Oncology, 2007
5282007
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
LM Liau, RM Prins, SM Kiertscher, SK Odesa, TJ Kremen, AJ Giovannone, ...
Clinical Cancer Research 11 (15), 5515-5525, 2005
5272005
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG
W Chen, T Cloughesy, N Kamdar, N Satyamurthy, M Bergsneider, L Liau, ...
Journal of Nuclear Medicine 46 (6), 945-952, 2005
5122005
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
A Lai, A Tran, PL Nghiemphu, WB Pope, OE Solis, M Selch, E Filka, ...
Journal of clinical oncology 29 (2), 142, 2011
5022011
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study
W Chen, S Delaloye, DHS Silverman, C Geist, J Czernin, J Sayre, ...
Journal of Clinical Oncology 25 (30), 4714-4721, 2007
4632007
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
PY Wen, WKA Yung, KR Lamborn, PL Dahia, Y Wang, B Peng, LE Abrey, ...
Clinical Cancer Research 12 (16), 4899-4907, 2006
4632006
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ...
Nature medicine 25 (3), 477-486, 2019
4392019
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang, P Wen, T Cloughesy, H Greenberg, D Schiff, C Conrad, K Fink, ...
Investigational new drugs 23 (4), 357-361, 2005
4382005
Glioblastoma: from molecular pathology to targeted treatment
TF Cloughesy, WK Cavenee, PS Mischel
Annual Review of Pathology: Mechanisms of Disease 9, 1-25, 2014
4352014
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20